Skip Nav Destination
Issues
1 December 2020
-
Cover Image
Cover Image
Human papillomavirus (HPV) is detected in a vast majority of cervical cancers. For advanced cervical dysplasia (CIN3), co-infection with the human immunodeficiency virus (HIV) can result in more aggressive disease and disease recurrence. Various studies identified that HIV protease inhibitors (HIV-PI) can exert anti-tumor effects outside of its anti-viral activity. In this month's cover image, Qiu and colleagues demonstrate treating cervical cancer tumors with HIV-PIs increase expression of tissue inhibitors of metalloproteinase 3 (TIMP-3, shown in red) on cancer-associated fibroblasts. Read the full article on page 2476. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Author Choice
Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Thomas A. Werfel; Donna J. Hicks; Bushra Rahman; Wendy E. Bendeman; Matthew T. Duvernay; Jae G. Maeng; Heidi Hamm; Robert R. Lavieri; Meghan M. Joly; Jill M. Pulley; David L. Elion; Dana M. Brantley-Sieders; Rebecca S. Cook
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers
Ramachandran Rashmi; Kay Jayachandran; Jin Zhang; Vishnu Menon; Naoshad Muhammad; Michael Zahner; Fiona Ruiz; Sisi Zhang; Kevin Cho; Yuting Wang; Xiaojing Huang; Yi Huang; Michael L. McCormick; Buck E. Rogers; Douglas R. Spitz; Gary J. Patti; Julie K. Schwarz
Author Choice
HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction
Yaqi Qiu; Federica Maione; Stefania Capano; Claudia Meda; Orietta Picconi; Serena Brundu; Alberto Pisacane; Anna Sapino; Clelia Palladino; Giovanni Barillari; Paolo Monini; Federico Bussolino; Barbara Ensoli; Cecilia Sgadari; Enrico Giraudo
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Gabrielle McDonald; Victor Chubukov; John Coco; Kevin Truskowski; Rohini Narayanaswamy; Sung Choe; Mya Steadman; Erin Artin; Anil K. Padyana; Lei Jin; Sebastien Ronseaux; Charles Locuson; Zi-Peng Fan; Tabea Erdmann; Alan Mann; Sebastian Hayes; Mark Fletcher; Kavitha Nellore; Siva Sanjeeva Rao; Hosahalli Subramanya; K. Satish Reddy; Sunil K. Panigrahi; Thomas Antony; Sreevalsam Gopinath; Zhihua Sui; Nelamangala Nagaraja; Lenny Dang; Georg Lenz; Jonathan Hurov; Scott A. Biller; Josh Murtie; Kevin M. Marks; Danielle B. Ulanet
A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Jason A. Somarelli; Roham Salman Roghani; Ali Sanjari Moghaddam; Beatrice C. Thomas; Gabrielle Rupprecht; Kathryn E. Ware; Erdem Altunel; John B. Mantyh; So Young Kim; Shannon J. McCall; Xiling Shen; Christopher R. Mantyh; David S. Hsu
Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma
Branden A. Smeester; Garrett M. Draper; Nicholas J. Slipek; Alex T. Larsson; Natalie Stratton; Emily J. Pomeroy; Kelsie L. Becklin; Kenta Yamamoto; Kyle B. Williams; Kanut Laoharawee; Joseph J. Peterson; Juan E. Abrahante; Susan K. Rathe; Lauren J. Mills; Margaret R. Crosby; Wendy A. Hudson; Eric P. Rahrmann; David A. Largaespada; Branden S. Moriarity
Large Molecule Therapeutics
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA
Johnnie J. Orozco; Aimee L. Kenoyer; Yukang Lin; Shyril O'Steen; Rosario Guel; Margaret E. Nartea; Alexandra H. Hernandez; Mark D. Hylarides; Darrell R. Fisher; Ethan R. Balkin; Donald K. Hamlin; D. Scott Wilbur; Kelly D. Orcutt; K. Dane Wittrup; Damian J. Green; Ajay K. Gopal; Brian G. Till; Brenda Sandmaier; Oliver W. Press; John M. Pagel
Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor
Arsheed A. Ganaie; Adrian P. Mansini; Tabish Hussain; Arpit Rao; Hifzur R. Siddique; Ashraf Shabaneh; Marina G. Ferrari; Paari Murugan; Jörg Klingelhöfer; Jinhua Wang; Noona Ambartsumian; Christopher A. Warlick; Badrinath R. Konety; Mohammad Saleem
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Cancer Biology and Translational Studies
Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome–Induced Cell Death in Head and Neck Squamous Cell Carcinoma
Jeremy J.P. Shaw; Timothy L. Boyer; Emily Venner; Patrick J. Beck; Tristen Slamowitz; Tara Caste; Alexandra Hickman; Michael H. Raymond; Pedro Costa-Pinheiro; Mark J. Jameson; Todd E. Fox; Mark Kester
Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Hiroyuki Arai; Yasmine Baca; Francesca Battaglin; Natsuko Kawanishi; Jingyuan Wang; Shivani Soni; Wu Zhang; Joshua Millstein; Curtis Johnston; Richard M. Goldberg; Philip A. Philip; Andreas Seeber; Joanne Xiu; Jimmy J. Hwang; Anthony F. Shields; John L. Marshall; W. Michael Korn; Heinz-Josef Lenz
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.